Cargando…
Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247045/ http://dx.doi.org/10.1186/bcr3011 |
| _version_ | 1782220031175688192 |
|---|---|
| author | Baselga, J Costa, F Gomez, H Hudis, C Rapoport, B Roche, H Schwartzberg, LS Petrenciuc, O Shan, M Gradishar, WJ |
| author_facet | Baselga, J Costa, F Gomez, H Hudis, C Rapoport, B Roche, H Schwartzberg, LS Petrenciuc, O Shan, M Gradishar, WJ |
| author_sort | Baselga, J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3247045 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-32470452011-12-29 Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer Baselga, J Costa, F Gomez, H Hudis, C Rapoport, B Roche, H Schwartzberg, LS Petrenciuc, O Shan, M Gradishar, WJ Breast Cancer Res Oral Presentation BioMed Central 2011 2011-11-16 /pmc/articles/PMC3247045/ http://dx.doi.org/10.1186/bcr3011 Text en Copyright ©2011 Baselga et al. |
| spellingShingle | Oral Presentation Baselga, J Costa, F Gomez, H Hudis, C Rapoport, B Roche, H Schwartzberg, LS Petrenciuc, O Shan, M Gradishar, WJ Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer |
| title | Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer |
| title_full | Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer |
| title_fullStr | Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer |
| title_full_unstemmed | Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer |
| title_short | Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer |
| title_sort | design of resilience: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic her2-negative breast cancer |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247045/ http://dx.doi.org/10.1186/bcr3011 |
| work_keys_str_mv | AT baselgaj designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT costaf designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT gomezh designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT hudisc designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT rapoportb designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT rocheh designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT schwartzbergls designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT petrenciuco designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT shanm designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer AT gradisharwj designofresilienceaphase3trialcomparingcapecitabineincombinationwithsorafeniborplacebofortreatmentoflocallyadvancedormetastaticher2negativebreastcancer |